Thought Leadership2018-10-15T14:23:33+00:00

News & Events

Observations, opinions, and opportunities presented by our experts


Rapid Diagnostics for Rheumatoid Arthritis Study Published in Journal of Medical Economics Article

PHE recently published a new study in collaboration with Genalyte on the potential value of rapid, cloud-enabled, onsite laboratory testing for the diagnosis of rheumatoid arthritis. The study found that this technology could generate value of over $5,000 per evaluated patient-year. The study was led by PHE’s Kata Bognar, Jason Shafrin, Michelle Brauer, Lauren Zhao, and Bapu Jena. […]

PHE’s Huber Leads New Study on Social, Economic Impacts of 2014 Ebola Crisis

Led by Caroline Huber, Associate Director of Policy and Economics, a surprising new study was recently published in The Journal of Infectious Diseases, estimating the overlooked social, economic and health impacts of the 2013-2016 West Africa Ebola crisis.


PHE’s Shafrin in JCP: Three Key Challenges to Make Precision Benefit Design Patient-Centered

In a new editorial for the Journal of Clinical Pathways, Jason Shafrin addresses the appeal of precision benefit design, identifying three key challenges to patient-centered implementation. […]

Restricting access based upon ICER estimates: value should not be one-size-fits-all

By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPP, MPL Senior Director, Policy and Economics


The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize […]

Load More Posts

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.